Carisma enters $5M subscription deal with Ocugen; Nasdaq deadline extended to Oct 21

Carisma Therapeutics Inc.

Subscription agreement with Ocugen for $5M private placement as part of concurrent $25M financing.
CEO Steven Kelly amended employment agreement with retention/transaction bonuses contingent on merger closing.
Nasdaq extends bid price compliance deadline to Oct 21; must complete merger by Oct 7 and show $4 bid price.
Merger with OrthoCellix must close by Oct 7 for continued listing on Nasdaq Capital Market.

item 1.01 item 3.02 item 5.01 item 5.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.